View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 19, 2017

IDbyDNA and ARUP Laboratories introduce diagnostic test for pneumonia

ARUP Laboratories and metagenomics firm IDbyDNA have introduced a new next-generation sequencing (NGS) test, Explify Respiratory, for the diagnosis of respiratory diseases such as pneumonia.

ARUP Laboratories and metagenomics firm IDbyDNA have introduced a new next-generation sequencing (NGS) test, Explify Respiratory, for the diagnosis of respiratory diseases such as pneumonia.

Explify Respiratory is designed to detect more than 200 common and rare bacterial, fungal and viral respiratory pathogens through a single test.

The ability of the new test to deliver more information in a clinically relevant turnaround time is expected to minimise the inappropriate use of antibiotics, eliminate sequential testing, and shorten hospital stays.

IDbyDNA’s DNA Taxonomer search engine software has been used in the test to allow rapid identification of an organism by its genetic material.

"We believe Explify Respiratory will provide the critical missing information that clinicians need to direct treatment decisions."

The test is part of an ongoing strategic collaboration between ARUP and IDbyDNA to develop and commercialise new metagenomics-based tests for infectious diseases.

Metagenomics leverages DNA and RNA analysis for quick detection of bacteria, viruses, fungi and parasites in patient samples.

IDbyDNA chief commercial officer Jeffrey Field said: “We believe Explify Respiratory will provide the critical missing information that clinicians need to direct treatment decisions and will initially be most helpful for very ill patients, test-negative patients with a high level of suspicion for a missed infection, and immuno-compromised patients who might be infected with a long list of diverse pathogens.”

According to the data obtained from a previous study, Explify Respiratory identified pathogens that were undetected by standard laboratory tests in 44% of immuno-compromised children who were treated for pneumonia in the intensive care unit.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network